Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-deoxy-N-(naphthalen–1–ylmethyl)guanosine 5'-(dihydrogen phosphate) is a synthetic purine nucleoside monophosphate analog. It consists of a deoxyguanosine backbone with an N-substituted naphthalenemethyl group at the guanine base and a dihydrogen phosphate group at the 5' position. This compound belongs to the class of organic compounds known as purine 2'-deoxyribonucleoside monophosphates[1][4]. Its primary use is experimental; it has not been approved for clinical use or assigned any therapeutic indication. The mechanism of action is not established but may involve interactions typical of modified nucleotides such as incorporation into DNA or interference with nucleotide-processing enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate).